🔎 Trials Near Me

Utama › Kanser Metastatik › California › Orange

Kajian klinikal Kanser Metastatik di Orange, CA

20 kajian untuk Kanser Metastatik sedang mencari peserta di lokasi dalam dan sekitar Orange (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Mengambil pesertaFasa 2
  • Children's Hospital of Orange County, Orange
  • Saint Joseph Hospital - Orange, Orange
Semua umur · Semua jantina · Dikemas kini 5 Okt 2026 · NCT05564377

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Mengambil pesertaFasa 1
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05372614

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Mengambil pesertaFasa 1/2
  • University of California Irvine, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05287945

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Mengambil pesertaFasa 1
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05803382

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Mengambil pesertaFasa 2
  • UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07007559

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Mengambil pesertaFasa 2/3
  • UC Irvine Health, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06989437

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Mengambil pesertaFasa 1/2
  • UCI Medical Center, Orange
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05118789

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Mengambil pesertaFasa 3
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Mengambil pesertaFasa 3
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07174336

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Mengambil pesertaFasa 1/2
  • UC IRVINE Health, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Mengambil pesertaFasa 1/2
  • University of California-Irvine Medical Center ( Site 0016), Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06863272

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Mengambil pesertaFasa 1
  • University of California - Irvine, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Mengambil pesertaFasa 1/2
  • Crinetics Study Site, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Mengambil pesertaFasa 1/2
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT05691491

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Mengambil pesertaFasa 3
  • Research Site, Orange
Umur 18 ke atas · Wanita · Dikemas kini 29 Jul 2026 · NCT07044336

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • Research Site, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT07284186

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Mengambil pesertaFasa 1/2
  • University of California Irvine Medical Center, Orange
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT05384626

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Mengambil pesertaFasa 1/2
  • UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • Stern Center for Cancer Clinical Trials and Research, Orange
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mac 2026 · NCT04900818

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Orange
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Kajian Kanser Metastatik di bandar lain

Kajian lain di Orange

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.